U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06825793) titled 'Semaglutide's Weight Loss Effects in Obesity' on Feb. 08.
Brief Summary: This is a non-randomized, concurrent, parallel-controlled clinical trial. The objective of this trial is to determine the relationship between weight loss responsiveness to semaglutide in obese patients and their gut microbiota.
Study Start Date: Feb. 20
Study Type: INTERVENTIONAL
Condition:
Obesity
Intervention:
DRUG: Semaglutide Subcutaneous Injection
All subjects received subcutaneous injections of semaglutide over a 28-week treatment period, which included an initial 16-week dose-escalation phase. The escalation protocol began with a starting dose of...